R&D Exec Takes Helm of Bayer Corporate Responsibility Foundations
Bayer’s current Vice President and Head of Corporate Innovation, R&D and Societal Engagement, Monika Lessl, PhD, is appointed to take charge of both the Bayer Science Foundation and the Bayer Cares Foundation.
Kemal Malik, Board Member for Innovation at Bayer, said: “We are pleased to welcome Monika Lessl to the Foundation’s Executive Committee,” adding, “With her broad expertise in science, social innovation, and foundation-leadership, Monika will further advance the Foundations’ mission in driving excellence in science and promoting social progress.” Dr. Lessl will take the helm of the Bayer Science Foundation as it fosters cutting-edge research, scientific talents, and science education, and the Bayer Cares Foundation as it focuses on promoting social innovation and employee engagement.
She aims to use both foundations to shape the future by nurturing new and emerging fields in science, driving social progress by working with social entrepreneurs. Dr. Lessl will foster the dialogue with stakeholders about the role and impact of innovation for the progress of society.
The Intouch Team Continues to Grow With Addition of Mike Motto
Intouch Solutions, the rapidly expanding marketing agency for life sciences, names Michael Motto as Senior Vice President of Market Access. Motto is now responsible for growing a scalable, best-in-class market access practice while driving direct and indirect revenue, effectively leveraging the agency’s collective expertise, data, and technology to build game-changing solutions for clients.
“I’m looking forward to working with a very talented group of colleagues in an environment that fosters innovation, collaboration, growth, and success,” states Motto. “My team and I are eager to help clients navigate market access challenges and further develop strategies and tactics to drive success.”
With more than 35 years experience gained from The Access Group, Novartis, Publicis, and RCW McCann, Motto has developed executive-level understanding of the macro business environment driven by evolving payer, patient, and provider influences. He will oversee all payer segments, provider systems, reimbursement models, group purchasing, and distribution models across the organization.
The specialty pharma company appoints Nancy R. Phelan, a member of the Board of Directors since October 2018, to serve as Chief Executive Officer. Phelan has 20 years of experience, including her time as Head of Worldwide Commercial Operations for Bristol-Myers Squibb, in healthcare and biotech with deep expertise in designing effective customer marketing strategies and building commercial capabilities that drive performance.
Nadia Dac joins Alder as Chief Commercial Officer with more than 25 years of U.S. and global commercial experience. Dac most recently served AbbVie as Vice President of Global Specialty Commercial Development, where she gained extensive expertise across all commercial functions including marketing, market access, promotion, and pipeline management. Her strategic and commercialization capabilities will be instrumental to Alder as it prepares to commercialize eptinezumab for migraine prevention and advance its pipeline.
The DNA Damage Response company appoints Ian Smith, MD, as Chief Medical Officer to lead Artios’ overall preclinical and clinical development strategy, regulatory, and medical activities. Dr. Smith previously served Eli Lilly as Senior Medical Director and AstraZeneca as Global Clinical Team Leader prior to that. As a clinical oncology expert, Dr. Smith will help develop an innovative DDR cancer therapies pipeline.
The clinical trial marketing company promotes David B. Fleishman, Director of the Account Services Department, to Principal and Director of Site Services. Fleishman will oversee the training and support of site study staff in all recruitment and engagement efforts while helping to set the strategic direction and drive continued growth for the firm as it develops innovative, patient-centric solutions that enhance the clinical trial participatory experience.
LEO Innovation Lab
LEO Pharma’s digital healthtech hub gains two new international board members: Joel Dudley, PhD, founding Director of the Institute for Next Generation Healthcare and Associate Professor at Mount Sinai, and Justin Ko, MD, Director and Chief of Medical Dermatology for Stanford Health Care. Dr. Dudley will draw upon his extensive knowledge within next-generation healthcare where digital solutions play a critical role to help the lab pioneer more disruptive developments in digital health technology. Dr. Ko, an expert in melanoma and early cancer detection and developer of a tele-dermatology care program, will provide insights into the application of machine learning and artificial intelligence to improve diagnosis and care delivery for patients all over the world.
NextLevel Health Partners
Astrid Larsen, PhD joins the Medicaid managed care company as Vice President of Population Health Management. In her new role, Dr. Larsen will be responsible for developing a data-driven approach to the Population Health Program. As an HCP with 10 years of experience, she is trusted to lead the Integrated Care Management Operations strategy to drive provider integration, membership growth, membership retention, and quality throughout the organization.
The Minnesota-based pharma company hires Kenneth H. Paulus to take the helm as President and CEO, based on his track record of transformational leadership. His 30-plus years of experience, including his time as CEO, President, and Chief Operating Officer at Allina Health, will help him guide Prime in areas such as telemedicine, innovative risk-sharing and payment models, and data-driven customer experience solutions.
Taryn Conway joins the biotech from Allergan where she was most recently Associate Vice President in Marketing. In her new position as Vice President, Marketing at Revance, Conway will lead product launch strategies and implementation to drive growth in a highly competitive marketplace as the company transitions from clinical-stage development to commercialization.
The clinical-stage biotech applying synthetic biology to beneficial microbes to develop living medicines, names Scott Plevy, MD, the new Chief Scientific Officer. He will be responsible for Synlogic’s research organization as well as leading the advance of its platform and pipeline.
Tom Schwenger will join the life sciences industry’s leading cloud-based software company as President and COO in September 2019. He has 25 years of life sciences industry expertise in building high-performing teams that lead strategy and technology transformations for many of the world’s top pharma, biotech, and medical device companies. He currently heads Accenture’s Northeast Products Industries Practice.